Skip to content

Drug interactions

Crizotinib + Dihydroergotamine

Severity: Major

Crizotinib and Dihydroergotamine: major interaction.

Last updated Sources: US FDA label

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Crizotinib inhibits CYP3A4 and may raise dihydroergotamine levels. Excess dihydroergotamine can cause peripheral and cerebral ischemia (ergotism), a serious and sometimes irreversible toxicity.

What this interaction means in plain words

Crizotinib and Dihydroergotamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Crizotinib belongs to Oncology; Dihydroergotamine belongs to Central Nervous System.

Evidence level: Moderate

Why it happens

Crizotinib inhibits CYP3A4-mediated metabolism of dihydroergotamine.

What to do

Avoid the combination and use a non-ergot migraine therapy. If used, monitor closely for vasospasm, numbness, cold extremities or ischemia.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Crizotinib and Dihydroergotamine, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

References

Frequently asked questions

Can I take Crizotinib with Dihydroergotamine?

MediHelp rates the interaction as major. Crizotinib and Dihydroergotamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Crizotinib inhibits CYP3A4 and may raise dihydroergotamine levels. Excess dihydroergotamine can cause peripheral and cerebral ischemia (ergotism), a serious and sometimes irreversible toxicity.

How serious is the interaction between Crizotinib and Dihydroergotamine?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and use a non-ergot migraine therapy. If used, monitor closely for vasospasm, numbness, cold extremities or ischemia.

What other medicines interact with Crizotinib?

MediHelp also lists interactions of Crizotinib with, for example, Flibanserin, Lomitapide, Lonafarnib. The full list is on the Crizotinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in